- Home
- SONN
as 11-22-2024 2:39pm EST
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 3.3M | IPO Year: | N/A |
| Target Price: | $117.33 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.50 - $18.72 | Next Earning Date: | 12-12-2024 |
| Revenue: | $55,881 | Revenue Growth: | -67.76% |
| Revenue Growth (this year): | -74.12% | Revenue Growth (next year): | N/A |
Latest Sonnet BioTherapeutics Holdings Inc. News
SONN Breaking Stock News: Dive into SONN Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
GlobeNewswire
16 days ago
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
16 days ago
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
GlobeNewswire
a month ago
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
TipRanks
a month ago
Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment
GlobeNewswire
a month ago
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
GlobeNewswire
2 months ago
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs
GlobeNewswire
2 months ago
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
Compare SONN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SONN Sonnet BioTherapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.